Jiangsu Recbio Technology Co Ltd Class H Logo
CNE1000057K9
A3EHWQ
2179.HK

Jiangsu Recbio Technology Co Ltd Class H

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Jiangsu Recbio Technology Co Ltd Class H had revenue of €966.62k and net profit of -€27.32m
(EUR) June 2026
YoY
Revenue 966.62k -
Gross profit 417.86k -
Net profit -27.32m -
EBITDA -17.79m -

Fundamentals

Metric Value
Market capitalization
€204.73m
Number of shares
451.97m
52-week high/low
€0.78 - €0.12
Dividends No
Beta
0.08
P/E ratio
-4.30
PEG ratio
-0.08
P/B ratio
4.09
P/S ratio
161.01

Company profile

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.

Name
Jiangsu Recbio Technology Co Ltd Class H
CEO
Yong Liu
Headquarters Taizhou, js
China
Website
IPO
31/03/2022
Employees 466

Ticker symbols

Exchange Symbol
Hkse
2179.HK
Frankfurt
G93.F
🍪

Parqet  uses cookies. Learn more